C
Claude Preudhomme
Researcher at university of lille
Publications - 510
Citations - 26309
Claude Preudhomme is an academic researcher from university of lille. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 81, co-authored 478 publications receiving 23213 citations. Previous affiliations of Claude Preudhomme include Heidelberg University & University of Limoges.
Papers
More filters
Journal ArticleDOI
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne,Cécile Pautas,Christine Terré,Emmanuel Raffoux,Dominique Bordessoule,Jean-Noël Bastie,Ollivier Legrand,Xavier Thomas,Pascal Turlure,Oumedaly Reman,Thierry de Revel,Lauris Gastaud,Noémie de Gunzburg,Nathalie Contentin,Estelle Henry,Jean-Pierre Marolleau,Ahmad Aljijakli,Philippe Rousselot,Pierre Fenaux,Claude Preudhomme,Sylvie Chevret,Hervé Dombret +21 more
TL;DR: The use of fractionated lower doses of gemtuzumab ozogamicin allows the safe delivery of higher cumulative doses and substantially improves outcomes in patients with acute myeloid leukaemia.
Journal ArticleDOI
A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic Leukemia
Pierre Fenaux,Claude Chastang,Sylvie Chevret,Miguel A. Sanz,Hervé Dombret,Eric Archimbaud,Martin F. Fey,Consuelo Rayon,Françoise Huguet,Jean-Jacques Sotto,Claude Gardin,Pascale Cony Makhoul,Philippe Travade,Eric Solary,Nathalie Fegueux,Dominique Bordessoule,Jesús F. San Miguel,Harmut Link,Bernard Desablens,Aspasia Stamatoullas,E. Deconinck,Frédéric Maloisel,Sylvie Castaigne,Claude Preudhomme,Laurent Degos +24 more
TL;DR: It is strongly suggest that early addition of chemotherapy to ATRA and maintenance therapy combining continuous CT and intermittent ATRA can reduce the incidence of relapse in APL.
Journal ArticleDOI
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Gerrit Jan Schuurhuis,Michael Heuser,Sylvie D. Freeman,Marie C. Béné,Francesco Buccisano,Jacqueline Cloos,David Grimwade,Torsten Haferlach,Robert Kerrin Hills,Christopher S. Hourigan,Jeffrey L. Jorgensen,Wolfgang Kern,Francis Lacombe,Luca Maurillo,Claude Preudhomme,Bert A. van der Reijden,Christian Thiede,Adriano Venditti,Paresh Vyas,Brent L. Wood,Roland B. Walter,Roland B. Walter,Konstanze Döhner,Gail J. Roboz,Gert J. Ossenkoppele +24 more
TL;DR: The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRd in clinical practice.
Journal ArticleDOI
A 17-gene stemness score for rapid determination of risk in acute leukaemia
Stanley W.K. Ng,Amanda Mitchell,James A. Kennedy,James A. Kennedy,James A. Kennedy,Weihsu C. Chen,Jessica McLeod,Narmin Ibrahimova,Andrea Arruda,Andreea C. Popescu,Vikas Gupta,Vikas Gupta,Vikas Gupta,Aaron D. Schimmer,Andre C. Schuh,Andre C. Schuh,Andre C. Schuh,Karen W.L. Yee,Karen W.L. Yee,Karen W.L. Yee,Lars Bullinger,Tobias Herold,Tobias Herold,Dennis Görlich,Thomas Büchner,Wolfgang Hiddemann,Wolfgang Hiddemann,Wolfgang E. Berdel,Bernhard Wörmann,Meyling Cheok,Claude Preudhomme,Hervé Dombret,Klaus H. Metzeler,Klaus H. Metzeler,Christian Buske,Bob Löwenberg,Peter J. M. Valk,Peter W. Zandstra,Mark D. Minden,John E. Dick,John E. Dick,Jean C.Y. Wang,Jean C.Y. Wang,Jean C.Y. Wang +43 more
TL;DR: The LSC17 score provides clinicians with a rapid and powerful tool to identify AML patients who do not benefit from standard therapy and who should be enrolled in trials evaluating novel upfront or post-remission strategies.
Journal ArticleDOI
p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies
Eric Wattel,Claude Preudhomme,B Hecquet,Michael Vanrumbeke,Bruno Quesnel,Isabelle Dervite,Pierre Morel,Pierre Fenaux +7 more
TL;DR: P53 mutations could induce drug resistance, at least in part, by interfering with normal apoptotic pathways in tumor cells, and are a strong prognostic indicator of response to chemotherapy and survival in AML, MDS, and CLL.